Cargando…

Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study

Liver stereotactic body radiotherapy (SBRT) is a local treatment that provides good local control and low toxicity. We present the first clinical results from our prospective registry of stereotactic MR-guided radiotherapy (MRgRT) for liver metastases. All patients treated for liver metastases were...

Descripción completa

Detalles Bibliográficos
Autores principales: Bordeau, Karl, Michalet, Morgan, Keskes, Aïcha, Valdenaire, Simon, Debuire, Pierre, Cantaloube, Marie, Cabaillé, Morgane, Jacot, William, Draghici, Roxana, Demontoy, Sylvain, Quantin, Xavier, Ychou, Marc, Assenat, Eric, Mazard, Thibault, Gauthier, Ludovic, Dupuy, Marie, Guiu, Boris, Bourgier, Céline, Aillères, Norbert, Fenoglietto, Pascal, Azria, David, Riou, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917771/
https://www.ncbi.nlm.nih.gov/pubmed/36769831
http://dx.doi.org/10.3390/jcm12031183
_version_ 1784886447607644160
author Bordeau, Karl
Michalet, Morgan
Keskes, Aïcha
Valdenaire, Simon
Debuire, Pierre
Cantaloube, Marie
Cabaillé, Morgane
Jacot, William
Draghici, Roxana
Demontoy, Sylvain
Quantin, Xavier
Ychou, Marc
Assenat, Eric
Mazard, Thibault
Gauthier, Ludovic
Dupuy, Marie
Guiu, Boris
Bourgier, Céline
Aillères, Norbert
Fenoglietto, Pascal
Azria, David
Riou, Olivier
author_facet Bordeau, Karl
Michalet, Morgan
Keskes, Aïcha
Valdenaire, Simon
Debuire, Pierre
Cantaloube, Marie
Cabaillé, Morgane
Jacot, William
Draghici, Roxana
Demontoy, Sylvain
Quantin, Xavier
Ychou, Marc
Assenat, Eric
Mazard, Thibault
Gauthier, Ludovic
Dupuy, Marie
Guiu, Boris
Bourgier, Céline
Aillères, Norbert
Fenoglietto, Pascal
Azria, David
Riou, Olivier
author_sort Bordeau, Karl
collection PubMed
description Liver stereotactic body radiotherapy (SBRT) is a local treatment that provides good local control and low toxicity. We present the first clinical results from our prospective registry of stereotactic MR-guided radiotherapy (MRgRT) for liver metastases. All patients treated for liver metastases were included in this prospective registry study. Stereotactic MRgRT indication was confirmed by multidisciplinary specialized tumor boards. The primary endpoints were acute and late toxicities. The secondary endpoints were survival outcomes (local control, overall survival (OS), disease-free survival, intrahepatic relapse-free survival). Twenty-six consecutive patients were treated for thirty-one liver metastases between October 2019 and April 2022. The median prescribed dose was 50 Gy (40–60) in 5 fractions. No severe acute MRgRT-related toxicity was noted. Acute and late gastrointestinal and liver toxicities were low and mostly unrelated to MRgRT. Only 5 lesions (16.1%) required daily adaptation because of the proximity of organs at risk (OAR). With a median follow-up time of 17.3 months since MRgRT completion, the median OS, 1-year OS and 2-year OS rates were 21.7 months, 83.1% (95% CI: 55.3–94.4%) and 41.6% (95% CI: 13.5–68.1%), respectively, from MRgRT completion. The local control at 6 months, 1 year and 2 years was 90.9% (95% CI: 68.3–97.7%). To our knowledge, we report the largest series of stereotactic MRgRT for liver metastases. The treatment was well-tolerated and achieved a high LC rate. Distant relapse remains a challenge in this population.
format Online
Article
Text
id pubmed-9917771
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99177712023-02-11 Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study Bordeau, Karl Michalet, Morgan Keskes, Aïcha Valdenaire, Simon Debuire, Pierre Cantaloube, Marie Cabaillé, Morgane Jacot, William Draghici, Roxana Demontoy, Sylvain Quantin, Xavier Ychou, Marc Assenat, Eric Mazard, Thibault Gauthier, Ludovic Dupuy, Marie Guiu, Boris Bourgier, Céline Aillères, Norbert Fenoglietto, Pascal Azria, David Riou, Olivier J Clin Med Article Liver stereotactic body radiotherapy (SBRT) is a local treatment that provides good local control and low toxicity. We present the first clinical results from our prospective registry of stereotactic MR-guided radiotherapy (MRgRT) for liver metastases. All patients treated for liver metastases were included in this prospective registry study. Stereotactic MRgRT indication was confirmed by multidisciplinary specialized tumor boards. The primary endpoints were acute and late toxicities. The secondary endpoints were survival outcomes (local control, overall survival (OS), disease-free survival, intrahepatic relapse-free survival). Twenty-six consecutive patients were treated for thirty-one liver metastases between October 2019 and April 2022. The median prescribed dose was 50 Gy (40–60) in 5 fractions. No severe acute MRgRT-related toxicity was noted. Acute and late gastrointestinal and liver toxicities were low and mostly unrelated to MRgRT. Only 5 lesions (16.1%) required daily adaptation because of the proximity of organs at risk (OAR). With a median follow-up time of 17.3 months since MRgRT completion, the median OS, 1-year OS and 2-year OS rates were 21.7 months, 83.1% (95% CI: 55.3–94.4%) and 41.6% (95% CI: 13.5–68.1%), respectively, from MRgRT completion. The local control at 6 months, 1 year and 2 years was 90.9% (95% CI: 68.3–97.7%). To our knowledge, we report the largest series of stereotactic MRgRT for liver metastases. The treatment was well-tolerated and achieved a high LC rate. Distant relapse remains a challenge in this population. MDPI 2023-02-02 /pmc/articles/PMC9917771/ /pubmed/36769831 http://dx.doi.org/10.3390/jcm12031183 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bordeau, Karl
Michalet, Morgan
Keskes, Aïcha
Valdenaire, Simon
Debuire, Pierre
Cantaloube, Marie
Cabaillé, Morgane
Jacot, William
Draghici, Roxana
Demontoy, Sylvain
Quantin, Xavier
Ychou, Marc
Assenat, Eric
Mazard, Thibault
Gauthier, Ludovic
Dupuy, Marie
Guiu, Boris
Bourgier, Céline
Aillères, Norbert
Fenoglietto, Pascal
Azria, David
Riou, Olivier
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
title Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
title_full Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
title_fullStr Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
title_full_unstemmed Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
title_short Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
title_sort stereotactic mr-guided radiotherapy for liver metastases: first results of the montpellier prospective registry study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917771/
https://www.ncbi.nlm.nih.gov/pubmed/36769831
http://dx.doi.org/10.3390/jcm12031183
work_keys_str_mv AT bordeaukarl stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT michaletmorgan stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT keskesaicha stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT valdenairesimon stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT debuirepierre stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT cantaloubemarie stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT cabaillemorgane stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT jacotwilliam stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT draghiciroxana stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT demontoysylvain stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT quantinxavier stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT ychoumarc stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT assenateric stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT mazardthibault stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT gauthierludovic stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT dupuymarie stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT guiuboris stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT bourgierceline stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT ailleresnorbert stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT fenogliettopascal stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT azriadavid stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy
AT riouolivier stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy